AI-Stroke’s Post

UPMC Enterprises, the venture capital and commercialization arm of UPMC, is an integral partner of the Institute for Precision Medicine, aiding its cross-disciplinary mission to advance #precisionmedicine. Focused on revolutionizing patient care, UPMC Enterprises finds, develops, and funds visionary thinkers in the #healthcare and biotech sectors and has incubated numerous #biotech startups like BlueSphere Bio, Avista Therapeutics and Novasenta, among others. In 2020, the UPMC Enterprises Translational Sciences division, made an incredible commitment ➡ a $1 billion investment in transformative medicines and health technologies. The investment powered over 40 Pitt-based projects, translating foundational scientific breakthroughs into real-world medical solutions. Pittsburgh, with its unique blend of academia, healthcare, and biotechnology, stands at the forefront of #innovation and personalized patient care. 💡 Learn more about how we partner with UPMC Enterprises in our new brochure 🔗 https://lnkd.in/e-Prz9nw

🚀 News from Our Propelling Grant Program! #3 🚀 We are thrilled to announce another #winner of the #PropellingGrant – Congrats to the innovators from MirEndo Jacopo Millul, PhD & Melpomeni Fani from the University of Basel & Universitätsspital Basel (USB)! MirEndo convinced the selection committee with cutting-edge technology to diagnose endometriosis through high-precision radiopharmaceuticals and positron emission tomography scans. Some time ago, we sat down with MirEndo and asked them some questions! Read the interview here: 𝗤: 𝗖𝗮𝗻 𝘆𝗼𝘂 𝗱𝗲𝘀𝗰𝗿𝗶𝗯𝗲 𝘄𝗵𝗮𝘁 𝗮𝗿𝗲 𝘁𝗵𝗲 𝗰𝗵𝗮𝗹𝗹𝗲𝗻𝗴𝗲𝘀 𝗠𝗶𝗿𝗘𝗻𝗱𝗼 𝘄𝗮𝗻𝘁𝘀 𝘁𝗼 𝘁𝗮𝗰𝗸𝗹𝗲? A: Endometriosis affects 1 in 10 women in the world. Nevertheless, no specific diagnostic exists. For this reason, patients consult different gynaecologists during their lives, and the official diagnosis (possible only with an invasive surgical procedure) comes 7-10 years after the first symptoms occur. Altogether, this patient journey has an economic impact of about 120 billion USD/year. With MirEndo, we are aiming to shorten this journey from years to a few months, by providing a reliable and fast diagnostic and staging solution for endometriosis. 𝗤: 𝗛𝗼𝘄 𝗶𝘀 𝘁𝗵𝗲 𝗣𝗿𝗼𝗽𝗲𝗹𝗹𝗶𝗻𝗴 𝗚𝗿𝗮𝗻𝘁 𝗵𝗲𝗹𝗽𝗶𝗻𝗴 𝘆𝗼𝘂 𝘁𝗼 𝗮𝗰𝗰𝗲𝗹𝗲𝗿𝗮𝘁𝗲 𝘆𝗼𝘂𝗿 𝗶𝗻𝗻𝗼𝘃𝗮𝘁𝗶𝗼𝗻 𝗮𝗹𝗼𝗻𝗴 𝘆𝗼𝘂𝗿 𝗲𝗻𝘁𝗿𝗲𝗽𝗿𝗲𝗻𝗲𝘂𝗿𝗶𝗮𝗹 𝗷𝗼𝘂𝗿𝗻𝗲𝘆? A: The #PropellingGrant from the University of Basel will support the development of MirEndo by providing support on specific needs, such as mentoring and skill-building. The visibility offered by the Innovation Office will expand the network and allow future collaborations, helping MirEndo grow its way to become a successful start-up. . . . . Pssssss... Are you curious about the next #PropellingGrant? This is the funding instrument to help researchers with an active University of Basel affiliation turn their discoveries or ideas into a start-up. For more information, please consult our website here: https://lnkd.in/dz8fhTq We also updated the dates for 2024! Have a look: Application deadline:  ▶ 2nd of April 2024, at noon! ▶ Interviews (if selected): 19th of April 2024 ▶ Deliberation phase: until mid-May 2024 ▶ Program starts: June 2024  #AcceleratingSuccess #PropellingInnovation #Impact

How does the #WesternAustralian government support medical innovation, and what are some notable outcomes of these efforts? Plaques on Perth’s St Georges Terrace celebrate notable contributors to Western Australia, including Nobel Prize winners Barry Marshall and Robin Warren for their groundbreaking medical discoveries. Western Australia continues to be a hub for medical innovation, thanks in part to the WA Life Sciences Innovation Hub (WALSIH). Dr. Tracey Wilkinson, director of stakeholder engagement at MTPConnect, highlights the state’s advancements in precision medicine, genetics, and regenerative medicine. Innovators like Fiona Wood, known for spray-on skin for burns, and Steve Wilton, a pioneer in treating Duchenne muscular dystrophy, underscore WA’s global impact. “They’ve had global impact from their work,” Wilkinson says. Significantly, their work has been commercialized. “It’s actually been positively impacting patients.” The Future Health Research and Innovation Fund supports this vibrant ecosystem, driving startups and medical breakthroughs. “Everyone knows that you need to translate the outcomes of research for it to impact anyone,” Wilkinson says. WA’s medical technology and digital health sectors are flourishing, with companies like OncoRes Medical, VitalTrace, Orthocell Ltd, and Argenica Therapeutics leading the charge in groundbreaking treatments and technologies. Western Australia’s commitment to medical research and innovation is transforming health outcomes and establishing the state as a leader in the field. Wilkinson emphasises the importance of patients and the positive impact on their lives. https://lnkd.in/gHGjZyz7 #MedTechNews #MedicalDevices #HealthcareInnovation #MedTechIndustry #HealthTech #HealthcareTechnology #MedDeviceNews #HealthcareNews #MedTechTrends

We are proud to see 𝐏𝐫𝐨𝐟. 𝐀𝐛𝐞𝐝 𝐄𝐥-𝐑𝐚𝐮𝐟 𝐇𝐢𝐣𝐚𝐳𝐢 featured in TheMarker for his groundbreaking contributions to medical innovation. As a leader in the fields of biochemistry and clinical research, Prof. Hijazi continues to advance healthcare with cutting-edge technologies and entrepreneurial spirit, inspiring the next generation of medical innovators. Two of our portfolio companies, Plas-Free and Pambio, were mentioned in the article as part of his ongoing efforts to transform healthcare: *️⃣ Plas-Free is focused on developing innovative medical tools to prevent bleeding in trauma and post-surgical cases, currently in clinical trials. *️⃣ Pambio is working on stopping brain bleeding during neurological events and reducing complications from neurological conditions, currently in preclinical trials. We’re excited to support these life-changing innovations and are grateful for Prof. Hijazi's leadership and vision in the healthcare sector. Learn More >> https://lnkd.in/d75MBrwg #MedicalInnovation #HealthcareLeadership #ClinicalResearch #HealthcareTransformation

Navigating the path to innovation and entrepreneurship can be challenging. To support its researchers, the University of Colorado Anschutz Medical Campus offers extensive resources. Our Department of Medicine recently showcased these during its Research Achievement Highlights (REACH) forum, featuring presentations by V. Michael Holers, MD, and Gali Baler, PhD. Holers, a professor in the Division of Rheumatology, shared his journey of co-founding companies to aid patients with immune diseases. "You can have a successful academic career and also found companies," he noted. CU Innovations supports researchers in turning ideas into technologies. Baler discussed various funding mechanisms, including accelerator programs like SPARK|REACH, Gates Grubstake Fund, and the Chancellor’s Discovery and Innovation Fund. “It’s crucial to decide on your involvement level and risk appetite," Baler advised, "as we ultimately aim to improve patient care.” Read more about the story below! https://bit.ly/3zvjTJA #Medicine #Colorado #MedicalInnovation

Aether Biomedical - Chiratae Pride of India Awards 2024 - Successful Fundraise. Congratulations, Team Aether Biomedical, Dhruv Agrawal and Dr. Faith Jiwakhan! Aether, a Chiratae portfolio company, uses musculoskeletal biomarkers to improve rehabilitation outcomes by more than 20 times. Aether is solving the problem of a lack of bidirectional communication between assistive therapy devices and the human body, leading to randomised, inefficient rehabilitation. The tech is focused on building the operating system for the rehabilitation industry utilising musculoskeletal sensors, ML algorithms and smart therapy devices. Intending to deploy the tech across the neuromuscular rehab domain, the initial implementation is in the upper limb amputation space with Zeus, a multi-modal bionic solution already on the market as a CE-certified and FDA-registered medical device. Zeus is the strongest bionic hand on the market, built completely using additive manufacturing, allowing amputees to do activities of daily life with ease. In addition, Zeus is the only locally repairable device on the market. Zeus comes with a web-based digital therapy platform that supports the end-to-end patient journey with tools like physical therapy monitoring, remote configuration, and device usage tracking. Aether's product suite is available across the EU, US, and India through partnerships with some of the largest clinics and distributors in these markets. #chirataeportfolio #chirataeprideofindiaawards2024 Sudhir Sethi Venkatesh Peddi Swaminathan Shankar Pavan Balakrishna Naimil Shah Tanvi Dubey https://lnkd.in/gfhVikU8

🌟We are excited to Present Biodesign Israel 4th Cohort graduate teams🌟 From groundbreaking projects to inspiring solutions, this cohort has demonstrated extraordinary creativity and commitment. We can’t wait to share their successes and the incredible potential they bring to the field. We’re thrilled to showcase their hard work and celebrate their accomplishments. Meet uFlow ⬇ Tomm Caspi Boaz Ozery Tali Gefen Gal Levy, MD Daniel Noghreyan uFlow is a cutting-edge medical startup founded in 2024, revolutionizing the treatment of urinary bladder dysfunction. Our product is a groundbreaking implantable device that targets three nerves responsible for bladder control. This innovative solution offers patients the ability to manage their bladder function through a user-friendly remote control, providing unprecedented autonomy and quality of life. We aim to bring relief to millions of people suffering from bladder control issues worldwide. #Biodesign #Innovation #Teamwork #Graduation #FutureLeaders Yona Vaisbuch Si Buchbut

“Reimbursement is really the key.” In this clip, Ken Mariash stresses the importance of companies having a reimbursement and market access strategy very early in the process. In this panel, we hear from experts who are innovating in the neurotechnology space. They discuss not only the exciting technological advancements and investment opportunities, but also tackle the complex regulatory, reimbursement, and ethical issues that these innovations introduce. Tune in to hear more from these incredible panelists:  • Tonya Dowd, MPH (Moderator) — PRIA Healthcare • Ken Mariash — Sinaptica Therapeutics • Angela Liedler — PRECISIS GmbH • Ana Maiques — Neuroelectrics • Carolina Aguilar — INBRAIN Neuroelectronics The full #LSIEurope23 panel, “Neurotech, the Next Frontier: Building, Investing, & Commercial Success in Brain Health, & the Ethical Implications of Neuroinnovation” is available on our website and YouTube channel.

Yesterday I had the privilege of attending Penn Health-Tech Demo Day, the culmination of the past year of acceleration for MedTech innovators in Penn's ecosystem. 3 takeaways + 1 moonshot + 1 apology 👑 Cash may be king but free cash is Queen Conventional wisdom is to seek institutional (angel & VC) investment to accelerate innovation. 2024's reality - institutional investors are looking for companies who have achieved clinical, regulatory and even commercial milestones with breakthrough technologies in large markets. Academic & Government agencies have capital available to help entrepreneurs de-risk their innovations clinically & technically. Many of these companies have benefited from non-dilutive capital to build out technology, gain customer insights, and begin clinical studies. ❓ Easy is sometimes hard and hard is sometimes easy A straightforward regulatory pathway with minimal clinical study requirements? Sounds easy - but clinicians & economic buyers look for robust data prior to adopting new technology. A crowded market? Sounds hard - but the existing market provides proof of innovation's clinical need, existing evidence & reimbursement for the new technology. 🏖 Know your beach(head) The strongest pitches outlined specific beachhead markets to drive early adoption of new technology - and a compelling story about how success in beachhead markets can translate to broad market adoption. Beachheads are important - and often not enough. As an example, DaVinci launched with a compelling value prop to improve outcomes in Urology, and later translated to OB/GYN, General Surgery and beyond . . . 🚀 "We choose to go to the moon in this decade and do the other things, not because they are easy, but because they are hard" - JFK. These teams are doing hard things - from miniaturized non-invasive neurological monitoring to re-thinking post-partum women's health to improving treatment for penetrating trauma - all in the name of advancing patient care. 👨💼 Apologies for the catawampus collar in this pic - perhaps an excuse to use "catawampus" on LinkedIn? Thank you to Courtney M. Houtsma, MS Glory Durham, MPH, MBA India Watson Katie Reuther, PhD, MBA for putting on such a great event with expert judging Bruce S. Tiffany Wilson and of course amazing pitches Shu Yang Justin Burrell, PhD Benjamin Ferleger Bryan Humbarger Eileen Wang Neil A. Ray, MD Jon Bar, MD

Where will your earliest stage funding come from for a technology with healthcare potential? Check out these five potential sources.